Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing ...
The CNPV program aims to reduce drug review times to 1-2 months, raising concerns about safety and regulatory scrutiny. Critics argue that accelerated timelines may lead to safety issues and strain ...
At the CIO100 Symposium, Department of Transportation CIO Pavan Pidugu discusses modernizing the DOT through AI and digital ...
As the second phase of the North Shore Action Plan, this vision represents the bold, long-overdue investment our residents ...
The shift towards sustainability in drug development focuses on reducing lab waste and enhancing operational efficiency for a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback